173 related articles for article (PubMed ID: 31670340)
1. Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes.
Jain PK; Lo JH; Rananaware S; Downing M; Panda A; Tai M; Raghavan S; Fleming HE; Bhatia SN
Nanoscale; 2019 Nov; 11(44):21317-21323. PubMed ID: 31670340
[TBL] [Abstract][Full Text] [Related]
2. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
3. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
4. Development of a pVEC peptide-based ribonucleoprotein (RNP) delivery system for genome editing using CRISPR/Cas9 in Chlamydomonas reinhardtii.
Kang S; Jeon S; Kim S; Chang YK; Kim YC
Sci Rep; 2020 Dec; 10(1):22158. PubMed ID: 33335164
[TBL] [Abstract][Full Text] [Related]
5. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
6. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
[TBL] [Abstract][Full Text] [Related]
7. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
Cai W; Luo T; Mao L; Wang M
Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
[TBL] [Abstract][Full Text] [Related]
8. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
Liu C; Zhang L; Liu H; Cheng K
J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
[TBL] [Abstract][Full Text] [Related]
9. A non-cationic nucleic acid nanogel for the delivery of the CRISPR/Cas9 gene editing tool.
Ding F; Huang X; Gao X; Xie M; Pan G; Li Q; Song J; Zhu X; Zhang C
Nanoscale; 2019 Oct; 11(37):17211-17215. PubMed ID: 31531437
[TBL] [Abstract][Full Text] [Related]
10. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
11. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
12. Progress of delivery methods for CRISPR-Cas9.
Yang W; Yan J; Zhuang P; Ding T; Chen Y; Zhang Y; Zhang H; Cui W
Expert Opin Drug Deliv; 2022 Aug; 19(8):913-926. PubMed ID: 35818792
[TBL] [Abstract][Full Text] [Related]
13. Redox-Responsive Phase-Separating Peptide as a Universal Delivery Vehicle for CRISPR/Cas9 Genome Editing Machinery.
Sun Y; Xu X; Chen L; Chew WL; Ping Y; Miserez A
ACS Nano; 2023 Sep; 17(17):16597-16606. PubMed ID: 37584415
[TBL] [Abstract][Full Text] [Related]
14. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
Xu Y; Liu R; Dai Z
Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
[TBL] [Abstract][Full Text] [Related]
15. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells.
Hindriksen S; Bramer AJ; Truong MA; Vromans MJM; Post JB; Verlaan-Klink I; Snippert HJ; Lens SMA; Hadders MA
PLoS One; 2017; 12(6):e0179514. PubMed ID: 28640891
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
17. Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Liu BY; He XY; Xu C; Ren XH; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23870-23879. PubMed ID: 31257851
[TBL] [Abstract][Full Text] [Related]
18. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Chen F; Alphonse M; Liu Q
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
20. Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms.
Dong Z; Qin Q; Hu Z; Chen P; Huang L; Zhang X; Tian T; Lu C; Pan M
Virol Sin; 2019 Aug; 34(4):444-453. PubMed ID: 31218589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]